Literature DB >> 10712568

Angiotensin II type 1 receptors stimulate protein synthesis in human cardiac fibroblasts via a Ca2+-sensitive PKC-dependent tyrosine kinase pathway.

M Hou1, E Pantev, S Möller, D Erlinge, L Edvinsson.   

Abstract

The aim of the present study was to investigate the proliferative effects of Ang II in human cardiac fibroblasts. The effects of Ang II in human cardiac fibroblasts on the 3H-thymidine incorporation, the cell number, the 3H-leucine incorporation and the total protein content were measured. The expression of receptor mRNA was performed by reverse transcription-polymerase chain reaction (RT-PCR). Ang II increased 3H-leucine incorporation in a concentration-dependent manner but not 3H-thymidine incorporation in primary cultures of human cardiac fibroblasts. The maximum effect (24 +/- 3% over control) was obtained at a concentration of 10 nM. There were no significant alterations of cell number or total protein content, suggesting that Ang II stimulated protein synthesis but did not induce hypertrophy. The accumulation of 3H-leucine was blocked by the AT1 receptor antagonist candesartan but not by the AT2 receptor antagonist PD123319. By using RT-PCR, both AT1 and AT2 receptors mRNA were found to be expressed in human cardiac fibroblasts. The selective MAPKK inhibitor PD098059, the protein kinase C inhibitor K252a or the phospholipase C inhibitor U73122 did not significantly inhibit Ang II augmented 3H-leucine incorporation. However, this was significantly blocked by the Ca2+-dependent protein kinase C inhibitor GO6976, the non-selective protein kinase inhibitor staurosporine and the tyrosine kinase inhibitor tyrphostin 25. The effects of Ang II were unaffected by the Gi-protein blocker pertussis toxin, indicating a Gi-protein-independent pathway. Ang II was synergistic with insulin but showed no significant increase on 3H-leucine incorporation when combined with PDGF or EGF. In summary, Ang II stimulates protein synthesis through AT1 receptors in human cardiac fibroblasts, but has no hypertrophic or hyperplastic effect. The response is mediated by a MAPKK-independent and Ca2+-sensitive PKC-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712568     DOI: 10.1046/j.1365-201x.2000.00684.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  6 in total

1.  Angiotensin II type 2 receptor-mediated inhibition of NaCl absorption is blunted in thick ascending limbs from Dahl salt-sensitive rats.

Authors:  Nancy J Hong; Jeffrey L Garvin
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II.

Authors:  Gary E Striker; Francoiçe Praddaude; Oscar Alcazar; Scott W Cousins; Maria E Marin-Castaño
Journal:  Am J Physiol Cell Physiol       Date:  2008-10-15       Impact factor: 4.249

4.  Angiotensin II AT1 receptor stimulates Na+ -K+ATPase activity through a pathway involving PKC-zeta in rat thyroid cells.

Authors:  S Marsigliante; A Muscella; M G Elia; S Greco; C Storelli
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

5.  Lithium Reduces Migration and Collagen Synthesis Activity in Human Cardiac Fibroblasts by Inhibiting Store-Operated Ca2+ Entry.

Authors:  Pao-Huan Chen; Cheng-Chih Chung; Yuan-Feng Lin; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

Review 6.  Protein kinase C in heart failure: a therapeutic target?

Authors:  Suresh Selvaraj Palaniyandi; Lihan Sun; Julio Cesar Batista Ferreira; Daria Mochly-Rosen
Journal:  Cardiovasc Res       Date:  2009-01-24       Impact factor: 13.081

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.